

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BARANOWSKA-KORTYLEWICZ ET AL.

APPLICATION NO: 10/521,299

FILED: FEBRUARY 14, 2006

FOR: ENHANCING THE EFFECT OF RADIOIMMUNOTHERAPY IN THE
TREATMENT OF TUMORS

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

In response to the Interview Summary dated February 11, 2008, response due within one month on March 11, 2008, kindly enter the following amendment.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims

Claim 1 (canceled)

Claim 2 (currently amended): A combination which comprises (a) ~~N-[5-[4-(4-methylpiperazinomethyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine~~ 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide and at least one compound selected from (b) a radioimmunoconjugate agent in which the active ingredients are present independently of each other in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use, wherein the radioimmunoconjugate is selected from the group consisting of ¹³¹I-CC49 and ¹³¹I-B72.3.

Claim 3 (canceled)

Claim 4 (previously presented): A combination according to claim 2 wherein a daily dose of 10 to 1000 mg of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is administered to an adult human.

Claim 5 (previously presented): A combination according to claim 2 wherein a pharmaceutically acceptable acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is administered.

Claim 6 (previously presented): A combination according to claim 5 wherein a monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is administered.

Claims 7-8 (canceled)

Claim 9 (previously presented): A combination according to claim 2 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is administered within a time period of 12 days before to 12 days after radioimmunotherapy.

Claims 10-17 (canceled)

Remarks

A correction is made to claim 1 to clarify the identity of combination partner (a). The correct identity of (a) is clear from the specification.

Entry of this paper is requested and an action on the merits is awaited.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Geo R Dohmann", written over a horizontal line.

George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824

Date: March 11, 2008

Electronic Acknowledgement Receipt

EFS ID:	2980604
Application Number:	10521299
International Application Number:	
Confirmation Number:	2167
Title of Invention:	Enhancing the effect of radioimmunotherapy in the treatment of tumors
First Named Inventor/Applicant Name:	Janina Baranowska-Kortylewicz
Customer Number:	1095
Filer:	George R. Dohmann/Linda Adams
Filer Authorized By:	George R. Dohmann
Attorney Docket Number:	ON/4-32590A
Receipt Date:	11-MAR-2008
Filing Date:	14-FEB-2006
Time Stamp:	15:40:37
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1		Amend3_11_08.PDF	69529	yes	3
			8966688e58b597ec9ea3dda2a961788a5c60df01		

	Multipart Description/PDF files in .zip description		
	Document Description	Start	End
	Amendment - After Non-Final Rejection	1	1
	Claims	2	2
	Applicant Arguments/Remarks Made in an Amendment	3	3
Warnings:			
Information:			
Total Files Size (in bytes):		69529	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>			